RB1 and breast cancer: Ribociclib showed a range of single-agent activity in Rb-proficient tumor models grown as xenografts in mice, while no appreciable antitumor effect was detected in 6 breast cancer patient-derived xenograft (PDX) models in which Rb was undetectable by immunohistochemistry (Supplementary Table 6).